ArticleScientific reports2025
Single-cell and bulk transcriptome profiling reveals RNA-binding protein regulatory programs in cervical cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The aberrant expression of RNA binding proteins (RBPs) is linked to various diseases, including cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC). However, the single-cell landscape of RBPs in CESC remains unclear. We analyzed single-cell data from 2 HPV + and 2 HPV- CESC samples to assess cell subtype composition and differential gene expression. Meanwhile, based on 2,141 reported RBPs, the expression patterns of different cell type-specific RBPs were further investigated. SUVA software was used to perform differential alternative splicing analysis on the TCGA CESC data. Finally, we did a lot of follow-up work and immunohistochemical studies to understand the true expression of RBP and its correlation with CESC prognosis. We observed a significant increase in the proportion of epithelial cells in the HPV + sample. The expression of RBP exhibited heterogeneity between HPV + and HPV- samples, with epithelial cells demonstrating the most diverse composition of RBP-expressing cell clusters. Results indicated that RNA splicing events were strongly associated with CESC progression. Covariation analysis identified 4 RBPs (CSTB, TIPARP, NDRG1, and NDRG2) correlated with 25 RNA alternative splicing events. Immunohistochemical experiments revealed that TIPARP expression was down-regulated in HPV + cervical cancer(p = 0.033). And the prognostic model that includes all RBPs, stage, and treatments may has have certain practical guiding significance for patients with CESC. Our study indicates that RBPs display specific expression patterns across HPV + and HPV- CESC. The regulatory checkpoints of these RBPs may serve as potential markers and therapeutic targets for the detection of HPV + CESC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.